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Abstract
Metabolomics data usually undergoes both pre-processing of the raw data and then further pre-
treatment before any statistical analysis is carried out. Different pre-treatment methods emphasise
various aspects of the data, and each method has advantages and disadvantages. The choice of pre-
treatment method depends on the biological question of interest, characteristics of the data and the
chosen data analysis. In this short paper, we investigate the effects of different pre-treatment methods
on four metabolomics data sets arising from chemical analysis of propolis samples collected from
honey bee colonies in three different locations in Scotland, and also samples from Libya. Propolis
has a variety of biological properties including anti-protozoal and anti-inflammatory effects. As a
complex mixture, its biological activity depends on its exact composition, which can be investigated
via metabolomic analysis. Two techniques of pre-treatment were applied, namely transformation and
scaling. The choice of method was found to greatly affect the results of the principal components
analysis (PCA) used to explain the variation in the data. The results indicated that there was no
notable (if any) improvement to be made by using any transformation techniques. It was also found
for all four data sets that Pareto scaling, incorporating mean centring, performed better than the
other scaling approaches considered here in terms of PCA, the analysis of interest, because the results
explain more of the variation in the data.
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1 Introduction
The metabolomics approach was pioneered by Nicholson et al. (1999) and Nicholson and Wilson (2003).
This provides an extremely powerful analytical technique for investigation of properties of biological
samples in pharmaceutical, medical and other applications. High-resolution mass spectrometry (MS) or
nuclear magnetic resonance spectroscopy (NMR) is used for metabolic profiling of samples, followed by
multivariate data analysis. The main purpose is identification of metabolites that may be associated with
changes in physiological or environmental conditions.
The aim of this study is to discuss effects of different pre-treatment methods used on MS-based
metabolomics data. The optimum pre-treatment methods may depend on the statistical analysis to be
carried out on the pre-treated data. In this study the effects of pre-treatment are examined in terms of
their effects on data to be examined using principal components analysis (PCA). Four metabolomics data
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sets were used to illustrate the results, namely results of MS analysis of propolis samples collected from
honey bee colonies in three different locations in Scotland as well as a further set of samples collected
from different locations in Libya. Propolis is a sticky resinous substance produced by honey bees, which
consists of a combination of beeswax and resins gathered by the bees from exudates of various surrounding
plants. It is used by the bees to seal and maintain their hives, but is also an anti-infective substance
which may protect against disease (Saleh et al., 2015; Simone-Finstrom and Spivak, 2010, 2012). Propolis
has various important biological properties, including anti-protozoal and anti-inflammatory effects. As a
complex mixture, its biological activity depends on its exact composition, which can be examined using
metabolomic analysis (Siheri et al., 2016).
Pre-treatment is an important part of any chemometric data analysis. It involves the application of
certain operations to data, to remove noise or unwanted variation or to reduce this to an acceptable level.
Pre-treatment follows pre-processing. Pre-processing is the general term for processes used to convert
the raw instrumental data arising from the chemical analysis into clean data, to make it suitable for
pre-treatment and further statistical or chemometric analysis which typically use multivariate analyses.
Pre-processing methods include noise filtering, deconvolution, peak detection, alignment and baseline cor-
rection, among others (Goodacre et al., 2007). On the other hand, pre-treatment involves transformation
and/or scaling of the pre-processed data to prepare it for data analysis (Brereton, 2009).
Metabolomics data are usually presented as a table or array, in which each column represents the
chromatographic peak areas or heights (spectral peak intensities) for a putatively identified compound
(metabolite) and each row represents a single sample or chemical analysis. Pre-treatment methods include
transformation of individual data elements, row scaling operations to make comparable the areas under
the spectrum for each sample, and/or column scaling operations on the data for each metabolite. Figure
1 shows sample data used in this paper.
Figure 1: An example of a metabolomics data set from propolis, where column A shows the ID from the
MassBank library (Horai et al., 2010) for each spectral peak, column B shows mz total ion chromatogram
displayed for the detected peaks, column C shows retention time, column D shows the names of com-
ponents where available, and columns E, F, G relate to a label for the hive or apiary. These data were
transposed before being processed.
The most common pre-treatment operations are logarithmic transformation, mean-centring, and stan-
dardisation. Pre-treatment may have positive or negative effects on the outcome of further data anal-
ysis. This paper describes the most important and commonly used pre-treatment methods used on
metabolomics data, and examines these using several metabolomics data sets described above and in
more detail below.
Section 2 presents materials and methods, including sample collection, transformation, and scaling,
and introduces principal component analysis (PCA), of interest for the analysis of these data. Section 3
presents results, and Section 4 provides discussion and conclusions.
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2 Materials and methods
2.1 Sample collection
Data from Scotland
Samples of raw propolis were collected during July and August 2014 by beekeepers from several hives of
honey bee colonies in three different areas of Scotland, namely Aberdeenshire in the north-east of Scotland,
Dunblane in central Scotland, and Fort William in the north-west of Scotland (see Figure 2). These
were profiled using liquid chromatography-high-resolution mass spectrometry. The propolis samples
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Figure 2: Map of the UK, including the locations of the apiaries supplying the analysed Scottish propolis
samples.
contain several hundred compounds, many of which are still unknown structures. The Aberdeenshire
data contains twenty seven samples (referred to as data set I). There are fourteen samples from Fort
William (data set II) and nine samples from Dunblane (data set III).
Data from Libya
Twelve raw propolis samples were available from different geographical localities in Libya (see map in
Figure 3); Tukra (Al Aquriyah), a small village located about 70km east of Benghazi city, Libya (P1);
Qaminis (53km south of Benghazi) (P2); Bayda (east of Benghazi city) (P3); Quba (east of Benghazi
city) (P4); Kufra A (south-east Libya) (P5); Kufra B (south-east Libya) (P6); Kufra C (south-east Libya)
(P7); Ghadames (south-west Libya) (P8); Tripoli (north-west Libya) (P9); Kasser Khiar (located 80 km
east of Tripoli) (P10); Khumas (located 120km east of Tripoli) (P11); and Khumas (120km east of Tripoli)
(P12). Samples P1-P12 were all used in this study.
Samples P1 and P2 were collected in December 2012, samples P3-P7 were collected in July 2013 and the
other samples P8-P12 are from March 2014.
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Figure 3: Map of Libya (after Siheri et al., 2016) including the locations of the apiaries supplying the
analysed Libyan propolis samples: P1 (Al Aquriyah), P2 (Qaminis), P3 (Bayda), P4 (Quba), P5 (Kufra
(A)), P6 (Kufra (B)), P7 (Kufra (C)), P8 (Ghadames), P9 (Tripoli), P10 (Kasser Khiar), P11 (Khumas
(A)), P12 (Khumas (B)).
2.2 Transformations
In general, metabolomics data show heteroscedasticity and are often skewed. Also, interactions between
the different metabolites are not necessarily additive but can be multiplicative (Boccard et al., 2010).
The multivariate statistical methods used for the analysis of metabolomics data are more effective when
the data are symmetric, and many statistical significance tests assume that the distribution of the data
is approximately normal. Therefore, it is useful to convert the data to approximate normality as closely
as possible (Brereton, 2009). Thus, transformations of the elements of metabolomics data sets are im-
portant in helping to achieve this aim. There are two common transformations used in this context, i.e.
logarithmic and power transformations.
1. Logarithmic Transformation
Logarithmic transformation is important as it reduces heteroscedasticity, converts multiplicative
models to additive ones, and reduces the influence of large data values such as outliers and occasional
high peaks. This is achieved by replacing a data element xij by its natural log, log(xij). Although
this has advantages, it has some limitations such as problems handling zeroes or near-zero values,
especially when these values are very close to the limit of detection. If data values are below the
limit of detection then they are considered as zero, and therefore their logarithms are not defined
(Brereton, 2009). To overcome this, usually a small value is added to xij in the event of xij being
zero, before taking the log.
2. Power Transformation
Power transformation is performed by replacing xij with x
n
ij , e.g. for n = 1/2, this is the square
root transformation, and so on. This has strengths such as (Brereton, 2009):
(a) It reduces the influence of large values such as outliers and occasional high peaks.
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(b) It can cope with zero values, removing the need to replace very small values below the limit
of detection.
(c) Any uncertainties in small values do not affect data analyses as much as in the case of logarith-
mic transformation. The smaller a value is relative to other values, the smaller its influence
on the nth root transformed data will be.
Drawbacks of this transformation can be summarised as:
(a) All values should be positive.
(b) If the distribution of the data is approximately log-normal, then power transformation cannot
convert it to a symmetric one.
(c) There are many possible values of the power. Trial and error is needed to identify the most
appropriate choice. Especially with multivariate data such as in metabolomics, where each
metabolite may have a different distribution, it can be difficult to decide on a suitable power.
2.3 Scaling
Before any exploratory analysis of metabolite data, the data must be cleaned, normalised and scaled
if there is any removable noise. Two approaches can be applied in data scaling: row scaling (scales
each row) and column scaling (scales each column). Column scaling techniques are applied after any pre-
processing, transformation and possible data normalisation by row scaling. Many approaches can be used
for scaling (row scaling or column scaling). Mean centring and scaling to unit variance (standardisation)
are two of the most popular methods. Here we focus on column scaling, assuming that the columns each
represent one spectral intensity across all samples (and we did not find row scaling to be necessary).
In mean centring, each column of the data table is scaled to a mean of zero by subtracting the column
mean from each value in the column. Mean centring may also be applied before standardisation. In
standardisation, each column of the data table is scaled to have unit variance by dividing each value
in the column by the standard deviation of the column (Craig et al., 2006). Scaling affects the results
of multivariate analysis, since it determines which correlations are important. This has implications for
methods of analysis such as PCA, which examines the covariance or correlation structure of multivariate
data. Other scaling methods include range scaling, Pareto scaling and vast scaling. Pareto scaling is
very similar to standardisation, but uses the square root of the standard deviation as the scaling factor
instead of the standard deviation itself. Vast scaling is an extension of standardisation. The details of
all these methods are given below.
1. Centring Generally, centring pre-treatment allows the researcher to focus on the differences not
the similarities in the data. The focus is on isolating and removing systematic variation in the
data. However, care is needed when data are heteroscedastic, as the effects of centring may not
be sufficient on their own. Usually, centring is applied in combination with other pre-treatment
methods. It belongs to the column scaling methods (Goodacre et al., 2007). Centring converts the
metabolite concentrations to fluctuate around zero instead of around the mean concentration for
that metabolite (column). Therefore it is used to focus on the fluctuations in the data (Jackson
(1991) and Bro and Smilde (2003)), leaving only the relevant variation (between the samples) for
analysis. Centring can be applied on its own or as part of any of the methods described below.
2. Scaling based on Data Dispersion
Several scaling techniques were tested that use a dispersion measure as a scaling factor. These also
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belong to the column-scaling techniques, as the scaling is applied to each column of the data set
(van den Berg et al., 2006). We consider standardisation (Jackson, 1991), Pareto scaling (Eriksson
et al., 1999), range scaling (Smilde et al., 2005), and vast scaling (Keun et al., 2003).
In these methods, the mean and standard deviation are defined as:
x¯j =
1
N
N∑
i=1
xij , and sj =
√√√√√√
N∑
i=1
(xij − x¯j)2
N − 1 , (1)
where i and j index the data rows and columns respectively, and N is the number of rows.
Standardisation
This is a form of scaling performed by mean centring each metabolite value using the respective
mean of all sample values for that metabolite, and then dividing by the standard deviation of all
the sample values for that metabolite. The formula is given by
x˜ij =
xij − x¯j
sj
. (2)
Standardisation is also called auto-scaling or unit variance scaling, as, after standardisation, all
metabolites have a standard deviation of one and have comparable scales. The main advantage is
that all metabolites become equally important, but this approach can increase the influence of mea-
surement errors (van den Berg et al., 2006). After standardisation, the data becomes dimensionless.
Range Scaling
The scaling factor in the range scaling method is the range within each metabolite. In this case,
the formula is
x˜ij =
xij − x¯j
xjmax − xjmin
(3)
referring to metabolite j. Range scaling allows comparison of metabolites with respect to their
biological response range. In this approach, all metabolites are equally important, and their scaling
is related to the biology. However, increased measurement errors and sensitivity to outliers may be
noticed when using this scaling method (van den Berg et al., 2006). As in the case of standardisation,
the data becomes dimensionless.
Pareto Scaling
Here the square root of the standard deviation is used as the scaling factor. It aims to reduce the
influence of large values without losing important information concerning the structure of the data.
The formula is:
x˜ij =
xij − x¯j√
sj
. (4)
Pareto scaled data is closer to the original data than standardised data, but this depends very much
on the large values in the data set.
Vast Scaling
This is an extension of standardisation. It aims to give more importance to those metabolites that
appear to have small variances. To achieve that, the method uses the coefficient of variation statistic
as a scaling factor. The formula is given by:
x˜ij =
(xij − x¯j)
sj
· x¯j
sj
, (5)
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where
x¯j
sj
is the inverse of the coefficient of variation of the jth metabolite (column j). This method
is not useful when large induced variation exists, and there is no group structure in the data.
All of these scaling methods belong to the column scaling methods, as the scaling is applied to the
columns (metabolites) in the data set.
3. Scaling based on Data Level
Level Scaling
Scaling based on average values uses a size measure instead of a measure of spread as the scaling
factor. Level scaling is one such method. It converts metabolite concentrations into changes relative
to the size of the average concentration of the metabolite, by using the mean concentration as the
scaling factor. The formula for level scaling of metabolite j is given by:
x˜ij =
xij − x¯j
x¯j
. (6)
This method is suitable for the identification of biomarkers. It is however prone to increase mea-
surement errors (van den Berg et al., 2006). Level scaling, like the scaling methods based on data
dispersion, also belongs to the column scaling methods.
2.4 Principal component analysis (PCA)
Metabolomics data records information on many compounds. To account for all of these manageably in
analysis, we must reduce the multidimensional information to a lower-dimensional space. Typically two
or three dimensions are used for visualisation of data. One way to achieve dimension reduction is by
using principal component analysis (PCA; Jackson, 1991). PCA is applied commonly in widely differing
areas from neuroscience to computer graphics, because it is relatively simple and effective.
PCA is one of several multivariate statistics techniques that can be used to visualise clusters and
patterns in data, by plotting it in lower-dimensional space, and this space is defined in PCA by the first
few principal component (PC) vectors.
PCA is a mathematical process that uses orthogonal transformations to convert a set of observations of
correlated variables to a set of values of uncorrelated variables (principal components (PCs); Vandeginste
et al., 1998). It describes the main directions of variation in a data set. The PCs are mutually orthogonal
vectors consisting of linear combinations of the input variables, ordered according to the amount of
variation which each PC represents, so that the first few PCs can be used as derived variables to represent
a high dimensional space by a lower-dimensional space accounting for most of the variation in the original
data space (McVean, 2009). These first few PCs can also be used to plot the data.
The number of principal components is determined by the rank of the data matrix, which is less than
or equal to the smaller of the number of rows and columns in the data. In the metabolomics context this
is likely to be less than or equal to the number of samples in the original data. In this study, the number
of PCs is equal to the number of samples.
PCA is sensitive to the scaling of the original variables, so is commonly used on the correlation matrix
of the variables or the covariance matrix of scaled variables rather than the covariances of the original
data. This overcomes the effect of possibly widely differing variances in the original variables, even when
those variables may be measured on the same scale. Not doing so leads to more dispersed variables
dominating the analysis.
Each PC is characterised by two sets of information, the scores and the loadings. Scores plots often
give useful information about the relationships between the samples (rows in the data). These plots can
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be produced as the projections of the samples to a single eigenvector (PC) versus sample number or onto
the plane formed by the first two eigenvectors (first two PCs). A projection of the samples to the two
eigenvectors associated with the largest eigenvalues shows the greatest amount of information about the
relationship between the samples that can be shown in two (linear) dimensions. The original space here
consists of metabolite expression profiles. Scatter plots of the first two or three PCs will reflect most of
the information in the original data set of higher dimension, and are a useful way to see any clusters of
groups of similar observations in the data.
The eigenvectors are found from an eigenanalysis of the covariance matrix or the correlation matrix
of the data matrix X or a singular value decomposition of X itself. PCA decomposes the variation of
data matrix X into scores T , loadings P , and a residuals matrix E, where P is a I×A matrix containing
the A selected loadings and T is a J ×A matrix containing the accompanying scores.
X = PTT + E, (7)
where PTTP = I, the identity matrix. The scores represent the values of the original observations in the
new space of variables defined by the PCs, and the loadings give the coefficients of each original variable
(centred and/or scaled, as appropriate) in the PCs (van den Berg et al., 2006).
3 Results
All calculations were performed using the R software (R Core Team, 2019). One data matrix X was input
to the R software for each set of propolis samples, after pre-processing of the data. Here matrix X is MS
data in which row labels are sample identifiers and columns are variables. After pre-processing, we apply
scaling techniques on the different data sets contained in each matrix X. Our goal is to carry out PCA
on these data, therefore the optimal scaling technique is considered as the one for which the maximum
variance is explained by the first few orthogonal principal components. Therefore, PCA is performed
to evaluate this, as an objective numerical measure to evaluate the methods, and PC scores plots and
loadings plots are also presented, to compare any patterns of clustering arising after the different scaling
methods are used.
3.1 Application of pre-treatment
As described, pre-treatment takes place in the second stage of data processing, after pre-processing, to
remove or reduce any uninduced variation (from sampling, sample work-up and analytical measurement
errors) as much as possible, and, if it exists, heteroscedasticity of the data. The usual order of applying
pre-treatment methods to a data set is to first transform the individual elements of the data set, then to
apply row scaling (if used), and finally to scale the columns, as was done here. Scaling methods (row or
column) have been classified as centring, scaling based on data dispersion and scaling based on average
values. The two most common methods of transforming the elements of a data matrix are the log and
the power transformations, and several commonly used scaling approaches have been described.
No element transformation was chosen in this case. Using a power transformation had very little
effect. Although using a log transformation brought the data much closer to normality, it also led to
much less interpretable results from PCA, for each of the data sets I, II, III and Libya. Row scaling was
also found to be unnecessary (results not shown).
Figures 4, 5, 6 and 7, respectively, show the scores and loadings plots for the propolis samples in
data sets I, II, III (Aberdeenshire, Fort William and Dunblane) and Libya. We can compare these across
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methods to examine the effects of column scaling on the PCA scores and loadings from the different
data sets. We are looking for patterns of clustering of samples in the scores plots, and for important
metabolites to be highlighted as spikes in the loadings plots.
The scores plots in Figures 4 to 6 (left plots) indicate that there are some differences among the scores
of the six scaling methods used on data sets I, II and III, for Scotland. Concerning the loadings plots
in Figures 4 to 6 (right plots), the loadings on PC1 and PC2 for standardisation, range, vast and level
scaling have a similar shape. For the other two scaling methods, the mean-centred true (raw) data and
Pareto, the plots of the loadings on both PCs have similar shapes. In general, the shapes of loadings for
the mean-centred true and Pareto approaches have the highest similarity among all the plotted loadings,
and the other approaches give different results from these but similar results to each other. Similar
conclusions can be drawn from Figure 7 for the Libyan data. These conclusions also apply to the scores
plots, where the results for the mean-centred true (raw) data and Pareto are similar but different from
the other results.
In summary, the application of different pre-treatment methods had a large effect on the resulting
data used as input for data analysis, as shown by the varying effects seen in Figures 4 to 7. For instance,
standardisation, range, vast and level scaling showed very many large peaks in the loadings, while after
Pareto scaling (or mean centring alone) relatively fewer large peaks were present, thus giving more
interpretable results indicating more important metabolites. While the results for the mean-centred true
data and Pareto-scaled data are similar, Pareto scaling identifies more peaks than mean centring alone,
while still being interpretable. It is clear that different results will be obtained when the differently
pre-treated data sets are used as input for data analysis.
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Figure 4: Plots of PC1 vs PC2 scores and loadings for the scaled Aberdeenshire data.
PCA constructs orthogonal uncorrelated linear combinations that explain as much common variation in
the data as possible. Tables 1, 2, 3 and 4 show the percentage of variation explained by the first two PCs,
used as an objective numerical comparison between all the scaling methods except for mean centring
alone, for PCA of data sets I, II, III and Libya. Each of these scaling methods includes mean centring.
From these tables, it can be observed that Pareto scaling performed much better than the other scaling
methods in terms of PCA, because it explains more of the variation in the data sets in every case. The
Accepted author version 10
−6e+09 −2e+09 2e+09−3
e+
09
0e
+0
0
3e
+0
9 Mean−centred true data
PC1
PC
2
−30 −20 −10 0 10 20 30
−
30
−
10
10
30
Mean−centred standardisation data
PC1
PC
2
−5 0 5
−
5
0
5
Mean−centred range scaled data
PC1
PC
2
−3e+05 −1e+05 1e+05 3e+05−2
e+
05
0e
+0
0
2e
+0
5 Mean−centred Pareto scaled data
PC1
PC
2
−5 0 5
−
5
0
5
Mean−centred Vast scaled data
PC1
PC
2
−40 −20 0 20 40
−
30
−
10
10
30
Mean−centred level scaled data
PC1
PC
2
(a) scores plots
0 100 200 300 400 500
−
0.
4
0.
0
Mean−centred true data
chemical compounds
Lo
ad
in
gs
PC1
PC2
0 100 200 300 400 500
−
0.
06
0.
00
0.
06
Mean−centred standardisation data
chemical compounds
Lo
ad
in
gs
PC1
PC2
0 100 200 300 400 500
−
0.
05
0.
05
Mean−centred range scaled data
chemical compounds
Lo
ad
in
gs
PC1
PC2
0 100 200 300 400 500−
0.
3
−
0.
1
0.
1
Mean−centred Pareto scaled data
chemical compounds
Lo
ad
in
gs
PC1
PC2
0 100 200 300 400 500
−
0.
05
0.
05
Mean−centred Vast scaled data
chemical compounds
Lo
ad
in
gs
PC1
PC2
0 100 200 300 400 500
0.
00
0.
05
0.
10
Mean−centred level scaled data
chemical compounds
Lo
ad
in
gs
PC1
PC2
(b) loadings plots
Figure 5: Plots of PC1 vs PC2 scores and loadings for the scaled Fort William data.
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Figure 6: Plots of PC1 vs PC2 scores and loadings for the scaled Dunblane data.
first two PCs explain 79.00%, 74.78%, 76.91% and 71.79% of the total variation of data sets I, II, III and
Libya respectively.
We conclude that Pareto scaling (incorporating mean centring) is the most useful type of scaling for
each of these samples. We see clearly from Tables 1 to 4 that the Pareto option leads to much the most
variation in data sets I, II, III and Libya being explained by the first two PCs, and therefore gives the
most informative lower-dimensional analysis of the data.
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Figure 7: Plots of PC1 vs PC2 scores and loadings for the scaled Libya data.
Pre-treatment methods Standardisation Range Pareto Vast Level
proportion variance of PC1 40.18 47.21 68.90 46.28 38.34
proportion variance of PC2 19.48 17.00 10.10 15.66 19.93
Cumulative Proportion 59.66 64.21 79.00 61.94 58.27
Table 1: Percentage of variance explained by the first two PCs of the Aberdeenshire data; best results
are shown in bold, and similarly below.
Pre-treatment methods Standardisation Range Pareto Vast Level
proportion variance of PC1 35.68 38.65 52.73 36.58 41.30
proportion variance of PC2 25.64 25.41 22.05 23.57 21.99
Cumulative Proportion 61.32 64.06 74.78 60.15 63.29
Table 2: Percentage of variance explained by the first two PCs of the Fort William data.
Pre-treatment methods Standardisation Range Pareto Vast Level
proportion variance of PC1 33.47 35.45 53.38 32.81 43.01
proportion variance of PC2 30.33 30.67 23.53 30.16 26.03
Cumulative Proportion 63.80 66.12 76.91 62.97 69.04
Table 3: Percentage of variance explained by the first two PCs of the Dunblane data.
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pre-treatment methods Standardisation Range Pareto Vast Level
proportion variance of PC1 37.87 40.24 54.87 47.16 33.46
proportion variance of PC2 19.55 19.58 16.91 15.80 21.80
Cumulative Proportion 57.42 59.82 71.79 62.68 55.25
Table 4: Percentage of variance explained by the first two PCs of the Libya data.
4 SUMMARY AND CONCLUSIONS
In this article we have given a short review of pre-treatment methods used in processing metabolomics
data, including transformation and scaling methods. There are two approaches that can be applied for
data scaling: row scaling, and column scaling, with different scaling methods available for either. Scaling
methods can be classified as centring, scaling based on data dispersion and scaling based on average
values. The advantages and disadvantages of applying these pre-treatment methods were discussed.
Column scaling makes the columns more comparable to each other for subsequent analysis, and makes
sense in the context of metabolomics data where the columns represent different metabolites detected in
the samples analysed.
We considered mean centring alone, and standardisation, range scaling, Pareto scaling, vast scaling
and level scaling, each including mean centring. We applied these six different column scaling methods
to four different metabolomics data sets arising from MS analysis of samples of honey bee propolis from
different locations in Scotland and Libya, to compare the effects of these on the results of principal
component analysis (PCA) of the treated data. We examined PC scores plots and loadings plots, for
graphical representations of the data in terms of the first two PCs, as well as the percentage of variance
explained by the first two principal components.
We conclude from the results that it is best for these data sets to be mean-centred and Pareto-scaled
prior to using PCA, where these operations are carried out on the columns of the data (metabolites).
This approach led to much the highest percentage of variance being explained by the PCA, relative to
other scaling approaches, for every data set. We did not find it necessary to first scale the rows of the
data to a constant total, nor to carry out data transformation first, as this had little effect on the data
used here.
These conclusions are likely to be true of other similar data sets as well, so we recommend these
choices for analysis of such MS-based metabolomics data, notably mean centring and Pareto scaling
of the data columns. Mortazavi-Tabatabaei et al. (2013), in a less extensive study, concluded, using
NMR metabolomics data from human blood samples, that mean centring separated two different patient
groups more clearly than auto-scaling, but did not examine Pareto scaling. The authors in van den Berg
et al. (2006) studied the effects of several pre-treatment methods and concluded that the pre-treatment
approach crucially affected the outcome of the data analysis, for functional genomics data. Therefore,
what is the best approach may depend on the context, as also concluded by Craig et al. (2006). It would
be interesting to carry out similar analyses on a wider variety of such data sets.
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